Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33539400.
- Also identified by DOI 10.1371/journal.pone.0246113 and PMC identifier 7861427.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 12-dose weekly regimen of rifapentine plus isoniazid (3HP) is recommended for the prevention of active tuberculosis (TB); however, it is unclear whether 3HP should be provided by directly observed therapy (DOT) or self-administered therapy (SAT). In addition, the introduction of patient informed choice between delivery modalities may have a positive impact on factors leading to treatment completion. The authors randomized 252 participants with HIV to a hypothetical scenario of providing preventive therapy by either DOT or an informed choice between DOT and SAT. Out of 104 participants who were randomized to a choice between DOT and SAT, 103 chose therapy by SAT. Participants rated their level of confidence and intention to complete therapy. Compared to those assigned to the DOT scenario, patients assigned to the choice scenario expressed greater confidence and intention to complete preventive therapy. Convenience and travel required to complete 3HP therapy were important factors in deciding between delivery modalities. Those assigned to DOT identified more barriers to completing therapy than those given a choice. Empowering patients to make informed decisions about how they receive TB preventive therapy may improve completion rates.
Medical subject headings
- Adult
- Decision Making
- Directly Observed Therapy
- Female
- HIV Infections
- HIV Infections/microbiology
- Humans
- Isoniazid
- Isoniazid/administration & dosage
- Isoniazid/therapeutic use
- Latent Tuberculosis
- Latent Tuberculosis/drug therapy
- Male
- Middle Aged
- Patient Preference
- Random Allocation
- Rifampin
- Rifampin/administration & dosage
- Rifampin/analogs & derivatives
- Rifampin/therapeutic use
- Self Administration
- Self Efficacy
- Uganda